Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Ryaltris in Perennial Allergic Rhinitis
NCT02709538Phase 3Completed
- Sponsor
- Glenmark Specialty
- Start
- Apr 2016
- Primary completion
- Jul 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of mometasone in perennial allergic rhinitis (PAR), sponsored by Glenmark Specialty. Started Apr 2016; status: completed.
02
Drugs
mometasone
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT02709538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709538.